Concert Pharmaceuticals Inc
NASDAQ:CNCE
Concert Pharmaceuticals Inc
Total Equity
Concert Pharmaceuticals Inc
Total Equity Peer Comparison
Competitive Total Equity Analysis
Latest Figures & CAGR of Competitors
Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Concert Pharmaceuticals Inc
NASDAQ:CNCE
|
Total Equity
$112.2m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Total Equity
$8B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
5%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Equity
$17.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Equity
$5B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-14%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Equity
$18.5B
|
CAGR 3-Years
27%
|
CAGR 5-Years
31%
|
CAGR 10-Years
31%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Equity
$27B
|
CAGR 3-Years
31%
|
CAGR 5-Years
23%
|
CAGR 10-Years
28%
|
See Also
What is Concert Pharmaceuticals Inc's Total Equity?
Total Equity
112.2m
USD
Based on the financial report for Dec 31, 2021, Concert Pharmaceuticals Inc's Total Equity amounts to 112.2m USD.
What is Concert Pharmaceuticals Inc's Total Equity growth rate?
Total Equity CAGR 5Y
6%
Over the last year, the Total Equity growth was -14%. The average annual Total Equity growth rates for Concert Pharmaceuticals Inc have been -13% over the past three years , 6% over the past five years .